A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).
Klarissa Hanja StürnerJan-Patrick StellmannJan DörrFriedemann PaulTim FriedeSven SchammlerStefanie ReinhardtSusanne GellissenGainet WeissflogTobias Djamsched FaizyOliver WerzSabine FleischerLea A I VaasFrank HerrmannOle PlessRoland MartinChristoph HeesenPublished in: Journal of neurology, neurosurgery, and psychiatry (2017)
NCT01450124; Results.
Keyphrases
- disease activity
- multiple sclerosis
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- phase iii
- study protocol
- juvenile idiopathic arthritis
- white matter
- phase ii
- oxidative stress
- clinical trial
- anti inflammatory
- randomized controlled trial
- open label
- double blind